Patients with metastatic cancer undergoing chemotherapy with fibroblast growth factor receptor inhibitors may experience a novel ocular toxicity.
The NCCN has issued updates to their guidelines for Hodgkin lymphoma, including additions to maintenance therapy options, systemic therapy options, and various treatment algorithms.
Results of a recent analysis showed that only three drug indications of six immuno-oncology agents met the durable survival threshold in the ASCO value framework.
A recent study identified patient characteristics that help predict poor 3-year survival in newly diagnosed standard-risk multiple myeloma.
According to a recent study, treatment with the multikinase inhibitor entrectinib produces durable responses in all of the following soft-tissue sarcomas EXCEPT...
Adjuvant EGFR TKI treatment for patients with EGFR-mutant NSCLC after complete resection offers a significant disease-free survival advantage, according to a recent meta-analysis.
High levels of a specific enzyme are linked with lower survival rates in patients with multiple myeloma, according to a new study.
Vaccine-based immunotherapy after surgery or radiotherapy did not increase survival in patients with localized non-small-cell lung cancer, according to a recent meta-analysis.
A myriad of factors including lack of guidelines, wealth of drug options, cost concerns, and varying efficacy make treatment decisions for rheumatoid arthritis a challenge.
A clinical pathway for coordinating the care of patients with heart failure may reduce admissions to the ED without increasing ED congestion.